Stock News

Analysts take a look at Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) having this to say.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) LogoInvestors sentiment decreased to 1.89 in Q2 2018. Its down 0.55, from 2.44 in 2018Q1. It turned negative, as 16 investors sold Dicerna Pharmaceuticals, Inc. shares while 12 reduced holdings. 35 funds opened positions while 18 raised stakes. 36.31 million shares or 18.35% more from 30.68 million shares in 2018Q1 were reported.
Moreover, Bluemountain Cap Llc has 0.01% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). 6,625 are owned by Legal General Grp Inc Public Limited. 98,872 were reported by Morgan Stanley. Quantbot Lp reported 12,807 shares stake. Birchview Limited Partnership holds 0.37% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) or 45,000 shares. 1,606 are owned by Bnp Paribas Arbitrage Sa. Citadel Advsrs Limited Liability Corporation has 0.01% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 1.71 million shares. Emory University owns 1.46% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 179,568 shares. Emerald Mutual Fund Advisers Tru reported 526,859 shares. 98,663 were accumulated by Tiaa Cref Invest Mgmt Ltd. Spark Mgmt Limited, a New York-based fund reported 100,200 shares. Renaissance Llc has invested 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Swiss Bancorp holds 0% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 54,100 shares. Artal Group Incorporated Sa reported 0.11% stake. 739,452 were reported by State Street Corporation.

Since August 15, 2018, it had 0 insider purchases, and 2 insider sales for $653,724 activity. Weissman James B sold $40,268 worth of stock or 2,301 shares.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Ratings Coverage

Among 4 analysts covering Dicerna Pharmaceuticals (NASDAQ:DRNA), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Dicerna Pharmaceuticals had 6 analyst reports since August 9, 2018 according to SRatingsIntel. The rating was upgraded by H.C. Wainwright to “Buy” on Wednesday, August 15. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has “Neutral” rating given on Monday, September 17 by FBR Capital. FBR Capital upgraded the stock to “Buy” rating in Tuesday, November 6 report. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has “Buy” rating given on Thursday, August 9 by Stifel Nicolaus. Citigroup maintained Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) rating on Tuesday, October 30. Citigroup has “Buy” rating and $30 target. Below is a list of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) latest ratings and price target changes.

06/11/2018 Broker: FBR Capital Old Rating: Neutral New Rating: Buy Old Target: $13.5 New Target: $21 Upgrade
30/10/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $27 New Target: $30 Maintain
17/09/2018 Broker: FBR Capital Old Rating: Neutral New Rating: Neutral Old Target: $10 New Target: $13.5 Maintain
13/09/2018 Broker: Citigroup Rating: Buy New Target: $27 Initiates Coverage On
15/08/2018 Broker: H.C. Wainwright Old Rating: Neutral New Rating: Buy Upgrade
09/08/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Buy Old Target: $18 New Target: $20 Maintain

The stock decreased 1.34% or $0.2 during the last trading session, reaching $14.72. About 334,541 shares traded. Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has risen 325.07% since November 10, 2017 and is uptrending. It has outperformed by 309.45% the S&P500.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally. The company has market cap of $909.80 million. The companyÂ’s preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases. It currently has negative earnings. It has a research collaboration and license agreements with Kyowa Hakko Kirin Co., Ltd.; City of Hope, an academic research and medical center; and Plant Bioscience Limited.

More notable recent Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) news were published by: Bizjournals.com which released: “Drug giant Lilly backs Cambridge’s Dicerna in $200M deal” on October 29, 2018, also Seekingalpha.com with their article: “Marinus Pharmaceuticals among healthcare gainers; Canopy Growth and Aurora Cannabis among losers” published on October 29, 2018, Seekingalpha.com published: “Dicerna Pharmaceuticals misses by $0.09, misses on revenue” on November 05, 2018. More interesting news about Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) were released by: Seekingalpha.com and their article: “Alexion up 4% premarket on Dicerna deal” published on October 24, 2018 as well as Seekingalpha.com‘s news article titled: “Dicerna Pharmaceuticals, Inc. (DRNA) CEO Douglas Fambrough on Q3 2018 Results – Earnings Call Transcript” with publication date: November 06, 2018.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *

*